New way to safer CAR-T cell therapiesInterleukin 1 (IL-1) blockers may prevent serious adverse events triggered by CAR-T cell therapies, according to two independent studies. more ➔
Janssen ends combo with daratumumabFollowing reports of an increase in mortality in a study that combined Genmab’s anti-CD38 daratumumab with a PD-L1 blocker, Genmab’s partner Janssen has stopped a study combining daratumumab with its PD1 … more ➔
Targovax drug boosts 2-year OS in pancreatic cancerTargovax ASA’s cancer immunotherapy TG01 significantly prolonged 2-year overall survival of patients with resected pancreatic cancer versus standard therapy. Targovax’ shares were up 16% on Thursday … more ➔
Researchers target metastasesItalian oncologists have found a more effective tumour angiogenesis blocker which curbs metastasis and tumour growth. more ➔
Vifor Pharma in €70m pruritus drug dealVifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated … more ➔
Evotec signs US$65m deal with CelgeneEvotec AG and Celgene Corporation have entered into a strategic drug discovery and development partnership to identify new therapeutics in oncology. more ➔
Biomaterials growth and crash side by sideBioeconomy industry experts gave a mixed outlook for biomaterials in mid-May in Cologne where about 200 stakeholder joined the 11th International Conference on Bio-based Materials. more ➔
Cell type switch helps colon cancer evade treatmentResearchers at LMU Munich have unraveled a new strategy of colon cancers to evade targeted therapies. more ➔
Kite expands cell therapy manufacturing in EuropeCAR-T cell therapy specialist Kite Pharma, now part of Gilead Sciences, has expanded its cell therapy manufacturing footprint in Europe. A 117,000 square-foot facility in Hoofddorp, the Netherlands, … more ➔
bluebird bio expands US$1bn deal with MediGene CAR-T cell developer bluebird bio Inc. has extended its potential US$1bn deal with cancer neoantigen TCR specialist MediGene by two new targets adding US$500m potential revenues to the licence agreement. … more ➔
